Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960030/S085

IsoFlex Leads

ABBOTT MEDICAL · Decision date Jun 26, 2026

FDA DECISIONP960030/S085

What did the FDA decide?

FDA records P960030/S085 as a supplement to PMA P960030, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 26, 2026.

FDA approval order statement

to move a site for a Lead component, Helix Shaft Assembly
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 26, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P960030/S085
Regulatory pathway
PMA supplement
Product code
NVN
Decision code
OK30
Decision date
Jun 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.

Product code
NVN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P960030/S085 received

    Application receipt date recorded by FDA.

  2. P960030/S084 · Related supplement

    UltiPace Low Voltage LPA1231, Tendril Low Voltage 2088TC, OptiSense Low Voltage 1999, Isoflex Low Voltage 1944/1948, Ten

  3. P960030/S085 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P960030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960030

Product / regulatory recordCompanyPathwayDecision dateSource
IsoFlex (1944)P960030/S081
ABBOTT MEDICALPMA supplementAug 27, 2025FDA
ABBOTT MEDICALPMA supplementNov 20, 2025FDA
IsoFlexP960030/S080
ABBOTT MEDICALPMA supplementFeb 19, 2026FDA
ABBOTT MEDICALPMA supplementJun 11, 2026FDA

Explore the linked device profile

Other records with product code NVN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Cardiac Rhythm Disease ManagementPMA supplementOct 16, 2026FDA
ABBOTT MEDICALPMA supplementOct 9, 2026FDA
Medtronic Cardiac Rhythm Disease ManagementPMA supplementAug 5, 2026FDA
ABBOTT MEDICALPMA supplementJun 26, 2026FDA
Medtronic Cardiac Rhythm Disease ManagementPMA supplementJun 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records